For millions of men, a cough, a laugh, or a sudden movement is not just a physical reflex but a moment of calculation and anxiety. It is the lived reality of stress urinary incontinence, a condition often arising after prostate surgery, where the muscles that control urine flow are damaged. The current toolkit for managing it is a study in trade-offs, oscillating between the bulky discretion of absorbent pads and the significant surgical risk of artificial urinary sphincters or male slings. A Connecticut startup, Urologic Design, is now preparing to test a third path: a temporary, non-surgical plug, smaller than a breath mint, designed to be inserted and removed by the user [Urologic Design, retrieved 2026].
Founded in 2022 by Dr. David Hesse, a board-certified urologist and associate professor at Yale School of Medicine, the company is in the quiet, high-stakes phase of medical device development. It has a working prototype, secured intellectual property, and has completed extensive bench testing. A recently closed $1.2 million pre-seed round, led by Angel Investor Forum with participation from HBS Alumni Angels of Boston and Connecticut Innovations, is earmarked for the next critical steps: finalizing the device for human use and preparing for its first clinical study [PR Newswire, October 2026].
The clinical wedge
The company's patented device is a single-use, sterile urethral occluder. It is designed to be inserted about one centimeter into the urethral opening, where it expands gently to prevent leakage. When the user needs to urinate, they remove it, use the bathroom, and can insert a new device. The entire proposition hinges on a simple but profound clinical insight: for many patients, the problem is not a complete lack of bladder control, but a specific vulnerability during physical stress. By offering a mechanical, on-demand solution, Urologic Design aims to sidestep the permanence and complications of surgery while providing more reliability and discretion than an absorbent pad [Urologic Design, retrieved 2026].
This approach targets a significant and often underserved patient population. While precise market sizing is not disclosed, stress urinary incontinence following prostatectomy is a well-documented sequela, affecting a substantial percentage of the hundreds of thousands of men who undergo the procedure annually in the U.S. alone. The standard of care today creates a clear wedge for innovation.
The team behind the prototype
The venture pairs deep clinical expertise with operational experience. Dr. Hesse, the chief scientific officer, founded the company after directly observing the limitations of existing options in his practice. His academic role at Yale provides a foundation in clinical research and access to a network of urological thought leaders [PR Newswire, October 2026]. He is joined by co-founder and CEO Henry Ritter, a Brown University graduate whose career has spanned strategy at McKinsey, media at The New York Times, and innovation within Alphabet's X division [Yale Ventures, retrieved 2026]. This combination is a classic early-stage medtech blueprint: the clinician-innovator who identifies the problem and envisions the solution, paired with an operator tasked with building the company, navigating regulation, and ultimately commercializing the product.
The following table outlines the founding team's key backgrounds:
| Role | Name | Key Background |
|---|---|---|
| Co-founder, Chief Scientific Officer | Dr. David Hesse | Board-certified urologist; Associate Professor of Urology, Yale School of Medicine. |
| Co-founder, CEO | Henry Ritter | BA Economics, Brown University; Former roles at McKinsey, The New York Times, and Alphabet's X. |
The long road to the clinic
The $1.2 million in capital is a starting line, not a finish line. The company's stated use of proceeds,product development, regulatory work, and preparation for a first-in-human study,signals the beginning of a long and capital-intensive journey [PR Newswire, October 2026]. The path ahead is defined by sequential, binary milestones that will determine the company's viability.
- Clinical validation. The upcoming first-in-human study is the first major test of the device's safety and basic efficacy in a controlled setting. Positive early data will be essential for securing the larger Series A funding required for a full pivotal trial.
- Regulatory strategy. The company will need to define its regulatory pathway with the U.S. Food and Drug Administration, likely seeking a de novo classification or a 510(k) clearance if a predicate device can be established. This process dictates the size, cost, and timeline of clinical trials.
- User adoption dynamics. Even with clinical and regulatory success, the product's ultimate adoption hinges on a delicate balance. It must be intuitive enough for daily self-insertion and removal by an aging population, while providing a tangible improvement in quality of life that justifies a new behavioral routine and cost over traditional pads.
Investor confidence, evidenced by the oversubscribed pre-seed round, appears to be betting on the team's ability to navigate this gauntlet and address a clear gap in care [PR Newswire, October 2026].
Navigating a crowded field of alternatives
The competitive landscape for Urologic Design is not defined by other venture-backed startups, but by entrenched standards of care and patient habits. The company's success depends on convincing urologists and patients to adopt a novel intervention where established, if imperfect, options already exist. The primary competitive pressures are not technological clones but clinical inertia and reimbursement hurdles.
The most credible near-term risk is that the device, despite its clever design, fails to demonstrate a sufficiently compelling benefit-risk profile in clinical studies to displace existing habits. Patient tolerance for daily insertion, the real-world rate of urinary tract infections, and the device's performance during high-stress activities are all unknowns that only rigorous trials can answer. The company's most plausible answer lies in Dr. Hesse's clinical grounding; the device was conceived not in a vacuum, but in response to repeated patient frustrations, suggesting its design parameters are intimately tied to unmet needs observed at the bedside.
What to watch in the next 18 months
The immediate horizon for Urologic Design is dominated by execution on its pre-seed mandate. The key milestones to watch are the initiation of its first-in-human study and the subsequent publication or presentation of that initial safety data. Securing a clinical site and principal investigator will be a tangible sign of progress. These steps will form the foundation for the next funding round, which will need to be significantly larger to bankroll the expanded trials required for regulatory submission.
For the patient population of men with post-prostatectomy stress incontinence, the standard of care today is a choice between management and intervention. Management means absorbent pads or protective garments, a daily reminder of the condition that controls leakage but can chafe, cause skin irritation, and create logistical and psychological burdens. Intervention means major surgery, such as an artificial urinary sphincter implantation, which carries risks of infection, mechanical failure, and revision procedures. It is a stark gap between a passive, often embarrassing coping mechanism and a definitive but high-risk operation. Urologic Design is betting that a significant number of men, and the urologists who treat them, will welcome a middle path,a temporary, patient-controlled device that offers active control without permanent alteration. The next phase of testing will determine if that bet is grounded in clinical reality.
Sources
- [Urologic Design, retrieved 2026] Urologic Design | A New Option for Male Incontinence | https://www.urologicdesign.com/
- [PR Newswire, October 2026] Urologic Design Raises $1.2M Pre-Seed Round to Develop Novel Medical Device for Urinary Incontinence | https://www.prnewswire.com/news-releases/urologic-design-raises-1-2m-pre-seed-round-to-develop-novel-medical-device-for-urinary-incontinence-302923536.html
- [Yale Ventures, retrieved 2026] Henry Ritter profile | https://venture.yale.edu/person/henry-ritter/
- [FinSMEs, October 2026] Urologic Design Raises $1.2M in Pre-Seed Funding | https://www.finsmes.com/2026/10/urologic-design-raises-1-2m-in-pre-seed-funding.html